'Wake-Up Pill' Under Study to Treat Patients with Bipolar Disorder

Aug 01, 2007

A preliminary study of 85 patients with bipolar disorder shows that a drug used to treat patients with sleep disorders might also control the depressive symptoms associated with bipolar disorder. At least 44 percent of the participants in the study reported improved symptoms, a noteworthy improvement for a disorder in which new treatments are needed, according to the study’s author, Mark Frye, M.D., director of the Mayo Clinic Mood Disorders Clinic and Research Program.

The study appears in the August issue of the American Journal of Psychiatry.

“There are very few treatments for the depressive phase of bipolar disorder and as a result there is an urgent need to evaluate potential new therapeutics,” says Dr. Frye. “Mood stabilizers in general are better at treating mania than depression, but the depressive phase of the illness is far more common. We really need continued research in this area.”

This study was completed in 2005 when Dr. Frye was with the University of California, Los Angeles (UCLA).

Bipolar disorder is characterized by an alternating pattern of emotional highs (mania) and lows (depression). It can range from a mild to severe condition, and there may be periods of normal behavior. (For more information about bipolar disorder, visit www.mayoclinic.com) According to the National Institute of Mental Health, 5.7 million adults in the United States are living with bipolar disorder.

Modafinil, the drug featured in this study, is often referred to in the news media as the “wake-up pill” because it is approved by the Food and Drug Administration (FDA) to treat patients who suffer from excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift
work sleep disorder. During the depressive phase of bipolar disorder the symptoms include
excessive sleepiness and fatigue, so researchers wondered if modafinil could address these symptoms in patients with bipolar disorder.

“This is a placebo-controlled study with real world community impact,” Dr. Frye says. Half of the patients in the study were given modafinil, 100-200 milligrams daily, and the other half were given a placebo over a six-week period. The randomized, double-blind, placebo-controlled trial was conducted at five sites (the University of California, Los Angeles; University of Texas Southwestern; University of Cincinnati; and University of Munich and the University of Freiburg in Germany).

While the trial was small, the 44 percent response rate was greater than that of the placebo group. Forty-four percent said they felt better, while 39 percent said their symptoms were in remission after six weeks. This compares to 23 percent and 18 percent in the control group. Modafinil was not associated with any greater risk of the manic and depressive mood swings associated with bipolar disorder.

How exactly modafinil works to promote wakefulness or improve mood in bipolar disorder is not completely understood. It appears to have an entirely different mechanism of action as compared to other psychostimulants, Dr. Frye says.

Source: Mayo Clinic

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

UK: Former reporter sentenced for phone hacking

24 minutes ago

(AP)—A former British tabloid reporter was given a 10-month suspended prison sentence Thursday for his role in the long-running phone hacking scandal that shook Rupert Murdoch's media empire.

Video: The diversity of habitable zones and the planets

30 minutes ago

The field of exoplanets has rapidly expanded from the exclusivity of exoplanet detection to include exoplanet characterization. A key step towards this characterization is the determination of which planets occupy the Habitable ...

Recommended for you

Determine patient preferences by means of conjoint analysis

10 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0